| C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates |
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago. |
zacks.com |
2025-05-07 13:15:45 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights |
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One Patient With a Minimal Residual Disease Negative Complete Response ; 40% ORR Achieved at the 75 µ g Dose Level |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-03-03 12:35:33 |
Czytaj oryginał (ang.) |
| C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-27 12:35:36 |
Czytaj oryginał (ang.) |
| C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates |
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago. |
zacks.com |
2025-02-27 11:20:37 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-26 12:36:10 |
Czytaj oryginał (ang.) |
| C4 Therapeutics to Participate in Upcoming March Investor Conferences |
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now |
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-01-02 13:07:32 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader |
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels |
globenewswire.com |
2024-12-08 14:30:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors |
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. |
globenewswire.com |
2024-11-20 09:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates |
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2024-10-31 11:20:23 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-28 18:01:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. |
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios |
globenewswire.com |
2024-10-15 20:01:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit |
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit, to be held October 28-31, 2024, in Boston, MA. Four members of the company's leadership team will deliver oral presentations or participate on panels to demonstrate the company's expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients' lives. |
globenewswire.com |
2024-10-09 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on September 30, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-09-30 20:01:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 |
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Global Phase 1 Trial Continues to Enroll; Monotherapy and Combination Expansion Cohorts Advancing With Additional Data Expected in 2025 C4T To Host Webcast Today at 12:00 pm ET; Webcast Link Available Here WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 mutations in solid tumors. |
globenewswire.com |
2024-09-13 14:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 |
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024 scheduled for September 13 – 17, 2024 in Barcelona, Spain. |
globenewswire.com |
2024-09-08 22:05:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors |
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. |
globenewswire.com |
2024-09-03 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics to Participate in Upcoming September Investor Conferences |
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences. |
globenewswire.com |
2024-08-29 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates |
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.73 per share a year ago. |
zacks.com |
2024-08-01 13:11:09 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights |
Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer |
globenewswire.com |
2024-08-01 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? |
C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-07-17 12:15:25 |
Czytaj oryginał (ang.) |
| C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 |
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain. |
globenewswire.com |
2024-07-16 20:01:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why |
C4 Therapeutics (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-07-09 17:01:25 |
Czytaj oryginał (ang.) |
| C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day |
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Protein Degradation (TPD) Day taking place virtually on July 15, 2024. |
globenewswire.com |
2024-07-08 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors |
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company's aspiration to become a fully integrated biotechnology company. |
globenewswire.com |
2024-06-10 11:00:00 |
Czytaj oryginał (ang.) |
| C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights |
Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299.2 Million as of March 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2024, as well as recent business highlights. |
globenewswire.com |
2024-05-08 11:00:00 |
Czytaj oryginał (ang.) |